

Rainbow Children’s Medicare: Expansion & Specialties to Drive Momentum

November 17, 2025 CMP: INR 1,342 | Target Price: INR 1,685

Expected Share Price Return: 25.6% | Dividend Yield: 0.22% | Potential Upside: 25.8%

BUY

Sector View: Positive

Change in Estimates	✓
Change in Target Price	✗
Change in Recommendation	✓

Company Info	
BB Code	RAINBOW IN EQUITY
Face Value (INR)	10.0
52 W High/Low (INR)	1,709 / 1,206
Mkt Cap (Bn)	INR 138.2 / USD 1.6
Shares o/s (Mn)	101.5
3M Avg. Daily Volume	1,78,369


Change in CIE Estimates						
FY26E			FY27E			
INR Bn	New	Old	Dev. (%)	New	Old	Dev. (%)
Revenue	18.0	18.3	-1.6	21.1	21.5	-1.7
EBITDA	6.0	6.1	-1.6	7.2	7.3	-1.7
EBITDAM %	33.5	33.5	0.0	34.1	34.1	0.0
APAT	3.3	3.4	-2.3	4.2	4.3	-2.4
EPS (INR)	33	34	-2.3	41	42	-2.4

Actual vs CIE Estimates			
INR Bn	Q2FY26A	CIE Estimate	Dev.%
Revenue	4.4	4.3	3.3
EBITDA	1.5	1.4	4.8
EBITDAM %	33.5	33.0	47bps
Adj. PAT	0.8	0.8	(5.6)

Key Financials					
INR Bn	FY24	FY25	FY26E	FY27E	FY28E
Revenue	13.0	15.2	18.0	21.1	25.9
YoY (%)	10.5	16.9	18.5	17.6	22.6
EBITDA	4.3	4.9	6.0	7.2	8.9
EBITDAM %	33.1	32.3	33.5	34.1	34.3
Adj PAT	2.2	2.4	3.3	4.2	5.6
EPS (INR)	21.4	24.0	32.7	41.2	55.2
ROE %	17.2	16.6	18.4	18.8	20.1
ROCE %	25.2	23.9	25.4	25.2	25.9
PE(x)	63.0	56.3	41.1	32.7	24.4
EV/EBITDA	33.8	29.6	24.0	20.0	16.2

Shareholding Pattern (%)			
	Sep 2025	Jun 2025	Mar 2025
Promoters	49.85	49.85	49.85
FII	21.85	23.60	23.69
DII	17.46	15.44	15.31
Public	10.82	11.11	11.14

Relative Performance (%)			
YTD	3Y	2Y	1Y
BSE Healthcare	87.3	54.2	2.5
RAINBOW	65.8	32.8	(14.2)



Deepika Murarka
Email: deepika.murarka@choiceindia.com
Ph: +91 22 6707 9513

Maitri Sheth
Email: maitri.sheth@choiceindia.com
Ph: +91 22 6707 9511

Expansion & specialties to drive momentum: Strategic network expansion through the hub-and-spoke model, deeper penetration into new markets and a sharper focus on tertiary and quaternary care are set to strengthen the growth trajectory. Additionally, the ongoing scale-up of the IVF vertical is expected to further propel strong and sustainable long-term growth.

View and Valuation: We anticipate growth to be driven by strong momentum in IVF services, higher ARPOB and expansion into new geographies through organic and inorganic growth. **We forecast Revenue/EBITDA/PAT to expand at a CAGR of 19.6%/22.0%/32.1% over FY25–FY28E.** Valuing the stock at an EV/EBITDA multiple of 22x on the average of FY27 and FY28E, we maintain our target price of **INR 1,685** and upgrade our rating to **BUY** (from ADD).

- Revenue came in above estimate and saw strong QoQ growth on all fronts**
- Revenue came in at INR 4.4 Bn (vs. CIE estimate: INR 4.3 Bn), up 6.5% YoY and 26% QoQ.
 - ARPOB at INR 57,396, up 15.3% YoY, but down by 9.4% QoQ; occupancy dropped from 59.9% in Q2FY25 to 52%.
 - EBITDA came in at INR 1.5 Bn (vs. CIE estimate: INR 1.4 Bn), up by 1.2% YoY and 43.7% QoQ. EBITDA margin came in at 33.5% (vs. CIE estimate of 33%), contracted by 176 bps YoY, but improved by 411 bps QoQ.
 - PAT came in at INR 0.8 Bn (vs. CIE estimate: INR 0.8 Bn), down 4.3% YoY and up 40.6% QoQ, with a PAT margin of 17% (vs. 18.9% in Q2FY25).

Acquisitions integrated smoothly; poised for revenue acceleration
The Warangal and Guwahati acquisitions were fully integrated in this quarter, including supply chain consolidation and updated insurance empanelment. Initial softness in volumes was due to transitional issues, such as permitting, insurer approvals and alignment of clinical protocols. With all operational hurdles now cleared, we expect noticeable revenue uplift beginning in December 2025. Both hospitals will benefit from RAINBOW’s specialty framework, clinical depth and centralised operating model. Over the next few quarters, these assets are expected to scale up rapidly, contributing to consolidated growth and margin improvement as they move towards maturity and better case mix realisation.

Expansion pipeline creates multi-year runway; large hubs to unlock operating leverage: RAINBOW continued advancing its significant expansion program, commissioning the 100-bed Rajahmundry hospital and preparing to launch two new Bangalore units (Electronic City and Hennur). Major projects, including the 450-bed Gurugram hub, Chennai’s 60-bed facility and Coimbatore regional hub (130 beds) - remain on track. Having added 780 beds in two years, the company now enters a monetisation phase with strong balance sheet support. Management expects these new hospitals to drive 20%+ CAGR over the next 2–3 years, with typical 15–18-month breakeven timelines and substantial margin expansion as high-capacity hubs scale up.

Particulars (INR Mn)	Q2FY26	Q2FY25	YoY (%)	Q1FY26	QoQ (%)
Net Sales	4,448	4,175	6.5	3,529	26.0
Materials consumed	622	517	20.4	475	31.0
Gross Profit	3,826	3,658	4.6	3,054	25.3
Gross Margin (%)	86.0	87.6	-161bps	86.5	-53bps
Employee + Operating Expenses	2,337	2,187	6.9	2,018	15.8
EBITDA	1,489	1,471	1.2	1,036	43.7
EBITDA Margin (%)	33.5	35.2	-176bps	29.4	411bps
Depreciation	358	349	2.7	342	4.8
EBIT	1,212	1,235	-1.8	895	35.5
Interest Cost	188	181	4.1	181	4.3
PBT	1,024	1,054	-2.8	714	43.4
PAT	756	790	-4.3	538	40.6
PAT Margin (%)	17.0	18.9	-192bps	15.2	176bps
EPS (INR)	7.4	7.8	-4.6	5.3	40.7

Source: RAINBOW, Choice Institutional Equities

Management Call – Highlights

Operational & Strategic Updates

- The company expects 20% CAGR revenue growth over the next 2 years, driven by recent capacity additions of 780 beds and ramp-up of acquisitions.
- Occupancy rate stood at 52%, with strong performance from recently opened hospitals.
- New hospital breakeven guidance: Spoke hospitals: 12-18 months and Regional hospitals like Rajahmundry: 15-18 months.
- Occupancy rate stood at 52%.
- North-east bed capacity now includes the acquisition and full integration of Pratiksha Hospital, Guwahati, with 150 beds capacity, effective from 1st September, 2025.
- It launched a new 100-bed hospital in Rajahmundry, creating a regional network with Visakhapatnam and Vijayawada locations.

Expansion pipeline

- Bengaluru: Electronic City (90 beds) & Hennur (60 beds) to go live by January FY26 is in the final stage of completion.
- Coimbatore 130 beds is expected to get commissioned by FY27 end.
- NCR (Gurugram): Sector 44 (325 beds) & Sector 56 (125 beds) is in process as the work is temporarily stopped by the government.
- Pune (150 beds) Greenfield project is in design phase with regulatory approvals pending.
- The company plans to invest INR 100 crore in capex in H2 FY26 and an additional INR 600 crore over the next 3 years for expansion in Pune, Coimbatore and Gurgaon.

Financial Position

- Net cash position of INR 560 crore as of Sept 30, 2025; no external debt needed for upcoming capex.
- Capex of INR 261 crore in this the quarter.
- Payer mix stable: 53% insurance vs. 47% cash patients.

Business Performance

- Outpatient volumes up 6% YoY; inpatient volumes were down 1% YoY and deliveries up 7% YoY.
- ARPOB (Average Revenue per Occupied Bed) grew 15% YoY
- Delivery volumes grew by 6.8% YoY.

Guidance


- Revenue growth expected in the 20% range for next 2 years, including M&As.
- Company is guiding for base EBITDA margin of 25%.
- New hospital breakeven guidance: Spoke hospitals: 12-18 months and Regional hospitals like Rajahmundry: 15-18 months.

Peer Comparison (Exhibit 1)


Bloomberg Ticker	Beds Capacity	Additional Beds by FY28	Bed Addition (%)	ARPOB	Occupancy	FY28E					
						ROCE	ROIC	ROE	Debt/Equity	EBITDA Margin	EBITDA Growth (FY25-28E)
APHS	10,200	2,070	20.3%	173,318*	69.0%	22.5%	23.3%	21.2%	0.3	15.9%	25.4%
FORH	5,793	2,800	48.3%	68,767	71.0%	19.1%	23.9%	15.0%	0.1	24.0%	29.4%
HCG	2,500	750	30.0%	44,751	67.1%	15.7%	20.9%	19.4%	1.1	19.8%	22.3%
JSLL	2,173	3,100	142.7%	8,200	53.1%	66.3%	41.0%	51.6%	-	34.9%	52.1%
MAXHEALT	5,200	3,400	65.4%	78,000	76.0%	22.4%	28.5%	18.9%	0.2	28.4%	30.1%
MEDANTA	3,062	1,400	45.7%	66,584	63.2%	21.6%	20.4%	16.9%	0.1	26.0%	22.6%
NARH	5,924	1,185	20.0%	48,352	60.0%	19.4%	21.8%	20.1%	0.2	24.0%	20.3%
RAINBOW	2,285	1,000	43.8%	57,396	52.0%	25.9%	24.7%	20.1%	0.2	34.3%	22.0%
YATHARTH	2,300	700	30.4%	32,395	65.0%	18.2%	22.0%	14.8%	-	25.1%	33.5%

*Average Revenue Per Patient


Source: RAINBOW, Choice Institutional Equities

After a peak in Q1FY26, ARPOB normalises


Source: RAINBOW, Choice Institutional Equities

Hospital capacity and utilisation show parallel uptick


Source: RAINBOW, Choice Institutional Equities

Delivery volumes recover after two quarters of decline


Source: RAINBOW, Choice Institutional Equities

Revenue grew significantly by 26% QoQ


Source: RAINBOW, Choice Institutional Equities

EBITDA margin improved by 411bps QoQ


Source: RAINBOW, Choice Institutional Equities

PAT significantly grew by 40.6% QoQ


Source: RAINBOW, Choice Institutional Equities

Bed capacity to cross 3,000 by FY28E


Source: RAINBOW, Choice Institutional Equities

ARPOB to grow by ~5% over the next few years


Source: RAINBOW, Choice Institutional Equities

Revenue to expand at 19.6% CAGR over FY25-FY28E


Source: RAINBOW, Choice Institutional Equities

EBITDA and EBITDA margin set for strong expansion

Source: RAINBOW, Choice Institutional Equities

PAT set to expand at 32.1% CAGR over FY25-FY28E

Source: RAINBOW, Choice Institutional Equities

ROE and ROCE trends

Source: RAINBOW, Choice Institutional Equities

Income Statement (INR Mn)

Particulars	FY24	FY25	FY26E	FY27E	FY28E
Revenue	12,969	15,159	17,959	21,127	25,910
Gross Profit	11,316	13,209	15,661	18,487	22,697
EBITDA	4,289	4,899	6,013	7,204	8,887
Depreciation	1,121	1,384	1,432	1,597	1,682
EBIT	3,168	3,514	4,581	5,607	7,205
Other Income	371	510	539	634	907
Interest Expense	591	725	660	633	606
PBT	2,948	3,300	4,459	5,608	7,506
Reported PAT	2,183	2,442	3,344	4,206	5,629
EPS (INR)	21.5	24.0	32.9	41.4	55.4
Ratio Analysis	FY24	FY25	FY26E	FY27E	FY28E
Growth Ratios (%)					
Revenue	10.5	16.9	18.5	17.6	22.6
EBITDA	8.2	14.2	22.7	19.8	23.4
PBT	4.6	11.9	35.1	25.8	33.8
PAT	2.9	12.2	36.6	25.9	34.0
Margins (%)					
Gross Profit Margin	87.3	87.1	87.2	87.5	87.6
EBITDA Margin	33.1	32.3	33.5	34.1	34.3
PBT Margin	22.7	21.8	24.8	26.5	29.0
Tax Rate	26.0	26.0	25.0	25.0	25.0
PAT Margin	16.7	16.1	18.5	19.8	21.6
Profitability (%)					
ROE	17.2	16.6	18.4	18.8	20.1
ROIC	23.2	20.8	23.7	23.7	24.7
ROCE	25.2	23.9	25.4	25.2	25.9
Financial Leverage					
OCF/EBITDA (x)	0.7	0.8	0.4	0.3	0.3
OCF/Net Profit (x)	1.5	1.6	0.7	0.6	0.4
Debt to Equity (x)	0.6	0.5	0.4	0.3	0.2
Interest Coverage (x)	5.4	4.9	6.9	8.9	11.9
Working Capital					
Inventory Days	53	52	52	52	52
Debtor Days	20	19	19	19	19
Payable Days	23	22	23	20	20
Cash Conversion Cycle	50	48	48	51	51
Valuation Metrics					
No of Shares (Mn)	101.5	101.6	101.6	101.6	101.6
EPS (INR)	21.4	24.0	32.7	41.2	55.2
BVPS (INR)	124.0	144.6	177.5	218.9	274.4
Market Cap (INR Mn)	1,37,490	1,37,557	1,37,557	1,37,557	1,37,557
PE	63.0	56.3	41.1	32.7	24.4
P/BV	10.9	9.4	7.6	6.2	4.9
EV/EBITDA	33.8	29.6	24.0	20.0	16.2
EV/Sales	11.2	9.6	8.1	6.8	5.6

Source: RAINBOW, Choice Institutional Equities

Balance Sheet (INR Mn)

Particulars	FY24	FY25	FY26E	FY27E	FY28E
Net Worth	12,589	14,682	18,026	22,232	27,862
Minority Interest	60	68	48	28	8
Borrowings & Lease liabilities	7,653	7,636	7,336	7,036	6,736
Trade Payables	815	910	1,132	1,158	1,420
Other Non-current Liabilities	77	97	107	119	129
Other Current Liabilities	510	377	648	759	797
Total Net Worth & Liabilities	21,704	23,770	27,297	31,332	36,952
Net Block	6,387	8,133	8,201	8,104	7,922
Capital WIP	138	278	378	478	578
Goodwill & Intangible Assets	41	103	113	123	133
Investments	0		0	0	0
Trade Receivables	704	773	935	1,100	1,349
Cash & Cash Equivalents	101	203	289	330	384
Other Non-current assets	8,922	7,036	8,086	8,536	11,067
Other Current assets	5,411	7,245	9,295	12,660	15,519
Total Assets	21,704	23,770	27,297	31,332	36,952

Cash Flows (INR Mn)	FY24	FY25	FY26E	FY27E	FY28E
Cash Flows from Operations	3,214	3,957	2,469	2,510	2,496
Cash Flows from Investing	(2,265)	(2,680)	(1,516)	(1,537)	(1,537)
Cash Flows from Financing	(1,018)	(1,179)	(964)	(932)	(905)

DuPont Analysis	FY24	FY25	FY26E	FY27E	FY28E
Tax Burden (%)	73.6	73.8	74.6	74.6	74.7
Interest Burden (%)	93.1	93.9	97.3	100.0	104.2
EBIT Margin (%)	24.4	23.2	25.5	26.5	27.8
Asset Turnover (x)	0.6	0.6	0.7	0.7	0.7
Equity Multiplier (x)	1.7	1.6	1.5	1.4	1.3
ROE (%)	17.2	16.6	18.4	18.8	20.1

Historical Price Chart: RAINBOW



Date	Rating	Target Price
January 26, 2024	ADD	1,292
May 22, 2024	BUY	1,441
August 16, 2024	BUY	1,345
October 29, 2024	BUY	1,611
February 11, 2025	HOLD	1,474
May 26, 2025	ADD	1,475
July 28, 2025	ADD	1,685
November 17, 2025	BUY	1,685

Institutional Research Team			
Utsav Verma, CFA	Head of Institutional Research	utsav.verma@choiceindia.com	+91 22 6707 9440
Prashanth Kumar Kota, CFA	Analyst – Basic Materials	prashanth.kota@choiceindia.com	+91 22 6707 9887
Dhanshree Jadhav	Analyst – Technology	dhanshree.jadhav@choiceindia.com	+91 22 6707 9535
Karan Kamdar	Analyst – Small and Midcaps	karan.kamdar@choiceindia.com	+91 22 6707 9451
Deepika Murarka	Analyst – Healthcare	deepika.murarka@choiceindia.com	+91 22 6707 9513
Putta Ravi Kumar	Analyst – Defence	ravi.putta@choiceindia.com	+91 22 6707 9908
Maitri Sheth	Analyst – Pharmaceuticals	maitri.sheth@choiceindia.com	+91 22 6707 9511
Ashutosh Murarka	Analyst – Cement & Infrastructure	ashutosh.murarka@choiceindia.com	+91 22 6707 9887
Dhaval Popat	Analyst – Energy	dhaval.popat@choiceindia.com	+91 22 6707 9949
Samarth Goel	Sr. Associate– Small and Midcaps	samarth.goel@choiceindia.com	+91 22 6707 9451
Aayush Saboo	Sr. Associate– Real Estate	aayush.saboo@choiceindia.com	+91 22 6707 9512
Bharat Kumar Kudikyala	Sr. Associate – Building Materials and Mining	bharat.kudikyala@choiceindia.com	+91 22 6707 9521
Avi Jhaveri	Sr. Associate – Technology	avi.jhaveri@choiceindia.com	+91 22 6707 9901
Kunal Bajaj	Sr. Associate – Technology	kunal.bajaj@choiceindia.com	+91 22 6707 9901
Abhinav Kapadia	Sr. Associate – Capital Goods	abhinav.kapadia@choiceindia.com	+91 22 6707 9707
Subhash Gate	Sr. Associate – Auto	subhash.gate@choiceindia.com	+91 22 6707 9233
Vikrant Shah, CFA (ICFAI)	Sr. Associate – Banks	vikrant.shah@choiceindia.com	+91 22 6707 9887
Vinay Rawal	Associate – Small and Midcaps	vinay.rawal@choiceindia.com	+91 22 6707 9433
Heer Gogri	Associate – Small and Midcaps	heer.gogri@choiceindia.com	+91 22 6707 9433
Heet Chheda	Associate – Auto	heet.chheda@choiceindia.com	+91 22 6707 9233
Rushil Katiyar	Associate – Technology	rushil.katiyar@choiceindia.com	+91 22 6707 9535
Stuti Bagadia	Associate – Pharmaceuticals	stuti.bagadia@choiceindia.com	+91 22 6707 9511

CHOICE RATING DISTRIBUTION & METHODOLOGY	
Large Cap*	
BUY	The security is expected to generate upside of 15% or more over the next 12 months
ADD	The security is expected to show upside returns from 5% to less than 15% over the next 12 months
REDUCE	The security is expected to show upside or downside returns by 5% to -5% over the next 12 months
SELL	The security is expected to show downside of 5% or more over the next 12 months
Mid & Small Cap*	
BUY	The security is expected to generate upside of 20% or more over the next 12 months
ADD	The security is expected to show upside returns from 5% to less than 20% over the next 12 months
REDUCE	The security is expected to show upside or downside returns by 5% to -10% over the next 12 months
SELL	The security is expected to show downside of 10% or more over the next 12 months
Other Ratings	
NOT RATED (NR)	The stock has no recommendation from the Analyst
UNDER REVIEW (UR)	The stock is under review by the Analyst and rating may change
Sector View	
POSITIVE (P)	Fundamentals of the sector look attractive over the next 12 months
NEUTRAL (N)	Fundamentals of the sector are expected to be in statis over the next 12 months
CAUTIOUS (C)	Fundamentals of the sector are expected to be challenging over the next 12 months

*Large Cap: More Than INR 20,000Cr Market Cap
*Mid & Small Cap: Less Than INR 20,000Cr Market Cap

Disclaimer

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Choice Equity Broking Private Limited-Research Analyst - INH000000222. (CIN. NO.: U65999MH2010PTC198714). Reg. Add.: Sunil Patodia Tower, J B Nagar, Andheri(East), Mumbai 400099. Tel. No. 022-6707 9999

Compliance Officer--Prashant Salian, Email Id – Prashant.salian@choiceindia.com Contact no. 022- 67079999- Ext-2310

Grievance officer-Deepika Singhvi Tel.022-67079999- Ext-834. Email- ig@choiceindia.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

This Research Report (hereinafter referred as "Report") has been prepared by Choice Equity Broking Private Limited as a Research Entity (hereinafter referred as "CEBPL RE" Limited). The Research Analysts, strategists are principally responsible for the preparation of "CEBPL RE" research. The research analysts have received compensation based upon various factors, which may include quality of research, investor client feedback, stock picking, competitive factors and firm revenues etc.

Whilst CEBPL has taken all reasonable steps to ensure that this information is correct, CEBPL does not offer any warranty as to the accuracy or completeness of such information. Any person placing reliance on the report to undertake trading does so entirely at his or her own risk and CEBPL does not accept any liability as a result. Securities and Derivatives markets may be subject to rapid and unexpected price movements and past performance is not necessarily an indication of future performance.

General Disclaimer: This 'Report' is strictly meant for use by the recipient and is not for circulation. This Report does not take into account particular investment objectives, financial situations or specific needs of individual clients nor does it constitute a personal recommendation. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through CEBPL nor any solicitation or offering of any investment/trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein.

These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this "Report" should rely on information/data arising out of their own Study/Investigations. It is advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This 'Report' has been prepared on the basis of publicly available information, internally developed data and other sources believed by CEBPL to be reliable. CEBPL or its directors, employees, affiliates or representatives shall not be responsible for, or warrant for the accuracy, completeness, adequacy and reliability of such information / opinions / views. Though due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of CEBPL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this report.

The price and value of the investments referred to in this Report and the income from them may tend to go down as well as up, and investors may incur losses on any investments. Past performance shall not be a guide for future performance. CEBPL does not provide tax advice to its clients, and all investors are strongly advised to take advice of their tax advisers regarding taxation aspects of any potential investment. Opinions are based on the current scenario as of the date appearing on this 'Report' only. CEBPL does not undertake to advise you as to any change of our views expressed in this 'Report' may differ on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold CEBPL, its employees and associates responsible for any losses, damages of any type whatsoever.

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject "CEBPL RE" to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by "CEBPL RE" in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this 'Report' shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. "CEBPL" requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to "CEBPL". Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in Mumbai (India).

Statements on ownership and material conflicts of interest, compensation - CEBPL and Associates reciprocates to the best of the knowledge and belief of CEBPL/ its Associates/ research Analyst who is preparing this report.

Disclosures of Interest (Additional):

- 1. "CEBPL", its research Analyst(s), or its associates or relatives of the Research Analyst does not have any financial interest in the company(ies) covered in this report.
- 2. "CEBPL" its research Analyst, or its associates or relatives of the research analyst affiliates collectively do not hold more than 1 of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- 3. "CEBPL", its research analyst, his/her associate, his/her relative, do not have any other material conflict of interest at the time of publication of this research report.
- 4. "CEBPL", its research analyst, and its associates have not received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in this report, in the past twelve months.
- 5. "CEBPL", its research analyst, or its associates have not managed or co-managed in the previous twelve months, a private or public offering of securities for the company (ies) covered in this report.
- 7. "CEBPL", or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party, in connection with the research report.
- 8. CEBPL research analyst has not served as an Officer, Director, or employee of the company (ies) covered in the Research report.
- 9. "CEBPL", its research analyst has not been engaged in market making activity for the company(ies) covered in the Research report.

Details of Associates of CEBPL and Brief History of Disciplinary action by regulatory authorities are available on our website i.e. <https://choiceindia.com/research-listing>

Sr. No.	Particulars	Yes / No
1.	Whether compensation has been received from the company(ies) covered in the Research report in the past 12 months for investment banking transaction by CEBPL	No
2	Whether Research Analyst, CEBPL or its associates or relatives of the Research Analyst affiliates collectively hold more than 1 of the company(ies) covered in the Research report	No
3.	Whether compensation has been received by CEBPL or its associates from the company(ies) covered in the Research report	No
4.	CEBPL or its affiliates have managed or co-managed in the previous twelve months a private or public offering of securities for the company(ies) covered in the Research report	No
5.	CEBPL, its research analyst, his associate, or its associates have received compensation for investment banking or merchant banking or brokerage services or for any other products or services from the company(ies) covered in the Research report, in the last twelve months	No

Copyright: The copyright in this research report belongs exclusively to CEBPL. All rights are reserved. Any unauthorized use or disclosure is prohibited. No reprinting or reproduction, in whole or in part, is permitted without the CEBPL's prior consent, except that a recipient may reprint it for internal circulation only and only if it is reprinted in its entirety.

This "Report" is for distribution only under such circumstances as may be permitted by applicable law. This "Report" has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This "Report" is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither CEBPL nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this "report" or lack of care in this report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Information barriers may be relied upon by CEBPL, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of CEBPL.

Investing in any non-U.S. securities or related financial instruments (including ADINR) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States. The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by CEBPL with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior written consent of CEBPL and CEBPL accepts no liability whatsoever for the actions of third parties in this respect.

The details of CEBPL, its research analyst and its associates pertaining to the companies covered in the Research report are given above.